Flag of the European Union EU Clinical Trials Register Help

Clinical trials for ANC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,652 result(s) found for: ANC. Displaying page 1 of 133.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-003610-25 Sponsor Protocol Number: CT-MT001-2-2015-1 Start Date*: 2015-12-09
    Sponsor Name:Myelo Therapeutics GmbH
    Full Title: A randomised, double-blind, placebo-controlled, parallel-design, multi-centre study to investigate the efficacy to reduce chemotherapy-induced neutropenia (CIN), effects on the haematopoietic syste...
    Medical condition: Chemotherapy-induced neutropenia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10072806 Chemotherapy toxicity attenuation PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000087-34 Sponsor Protocol Number: XM22-08 Start Date*: 2015-06-05
    Sponsor Name:Merckle GmbH
    Full Title: An Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Lipegfilgrastim 100 μg/kg B...
    Medical condition: Neutropenia in pediatric patients diagnosed with Ewing family of Tumors or rhabdomyosarcoma receiving chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) SK (Completed) CZ (Completed) BG (Completed) DE (Ongoing) ES (Completed) RO (Completed) PL (Completed) BE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003166-14 Sponsor Protocol Number: RGB-02-101 Start Date*: 2013-11-20
    Sponsor Name:Gedeon Richter Plc.
    Full Title: Multiple, fixed-dose, comparative efficacy and safety evaluation of RGB-02 and Neulasta® in patients undergoing chemotherapy treatment known to induce neutropenia.
    Medical condition: Neutropenia and febrile neutropenia in patients being treated with cytotoxic chemotherapy for malignancy.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    16.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2016-004539-18 Sponsor Protocol Number: PGCN-001 Start Date*: 2018-08-27
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia
    Medical condition: Chronic neutropenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013471 10066702 Chronic neutropenia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002039-28 Sponsor Protocol Number: LA-EP06-302 Start Date*: 2012-09-14
    Sponsor Name:Sandoz GmbH
    Full Title: Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®
    Medical condition: Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002057-35 Sponsor Protocol Number: ZIN-130-1504 Start Date*: 2015-10-28
    Sponsor Name:Hospira, Inc.
    Full Title: A Phase 1-2 ascending dose study to assess the pharmacodynamics, pharmacokinetics, and safety of HSP 130 in subjects with non metastatic breast cancer following single dose and multiple dose admini...
    Medical condition: Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clin...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004870 10021456 Immunodeficiency secondary to oncology chemotherapy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-001965-98 Sponsor Protocol Number: PGFN-001 Start Date*: 2017-01-10
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A randomized and open-label dose-finding, phase 2, efficacy, safety, and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO™ versus pegfilgrastim (Neulasta®) in non-metastat...
    Medical condition: chemotherapy-induced neutropenia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003094-10 Sponsor Protocol Number: SPI-GCF-12-201 Start Date*: 2014-01-16
    Sponsor Name:Spectrum Pharmaceuticals
    Full Title: Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim use for the Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherap...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who are Candidates for Adjuvant and Neoadjuvant Chemotherapy with the Docetaxel + Cyclophosphamide (TC) Regimen
    Disease: Version SOC Term Classification Code Term Level
    16.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-004532-58 Sponsor Protocol Number: LA-EP06-301 Start Date*: 2012-08-20
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressi...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001450-84 Sponsor Protocol Number: XM02-03-INT Start Date*: 2004-09-14
    Sponsor Name:BioGeneriX
    Full Title: Safety and Efficacy of XM 02 in patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy. Multinational, multicentre, randomised, controlled study
    Medical condition: Patients with small cell or non small cell lung cancer receiving platinum-based chemotherapy and developing Neutropenia due to chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003469-24 Sponsor Protocol Number: SPI-GCF-302 Start Date*: 2017-03-14
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving D...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who receiving Chemotherapy with the Docetaxel + Cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-024481-22 Sponsor Protocol Number: EP06-302 Start Date*: 2012-01-17
    Sponsor Name:Sandoz GmbH
    Full Title: A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemothe...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006203 Breast cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2012-005432-28 Sponsor Protocol Number: NEUGR-005 Start Date*: 2013-10-15
    Sponsor Name:Teva Pharmaceuticals Industries Ltd.
    Full Title: An open label, randomized, active controlled, dose finding study to evaluate the pharmacodynamics, pharmacokinetics, efficacy and safety of balugrastim at doses of 300 μg/kg and 670 μg/kg in pediat...
    Medical condition: Neutropenia induced by chemotherapy in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065252 Solid tumor LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002678-21 Sponsor Protocol Number: APO-Peg-03 Start Date*: 2012-01-10
    Sponsor Name:Apotex Inc
    Full Title: A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREA...
    Medical condition: Febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001153-10 Sponsor Protocol Number: X4P-001-103 Start Date*: 2020-02-05
    Sponsor Name:X4 Pharmaceuticals Incorporated
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Mavorixafor in Patients with WHIM Syndrome with Open-Label Extension
    Medical condition: WHIM Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010512 Congenital immunodeficiency LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) HU (Completed) ES (Ongoing) PL (Completed) AT (Completed) DE (Completed) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000891-34 Sponsor Protocol Number: ERA2006001 Start Date*: 2006-05-05
    Sponsor Name:Hôpital Ambroise Paré
    Full Title: A randomized, international, open-label, phase II study of peripheral blood progenitor cell (PBPC) mobilization and engraftment with pegfilgrastim or filgrastim for autologous transplantation in su...
    Medical condition: Multiple Myeloma .
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011899-30 Sponsor Protocol Number: 20080259 Start Date*: 2009-12-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Administered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizum...
    Medical condition: Locally-advanced or Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) CZ (Completed) BE (Completed) IE (Completed) IT (Completed) FR (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001772-55 Sponsor Protocol Number: XM02-ONC-201 Start Date*: 2015-01-26
    Sponsor Name:TEVA Pharmaceutical Industries Ltd
    Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 μg/kg tbo-filgrastim...
    Medical condition: Chemotherapy induced Neutropenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10029355 Neutropenias HLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) PL (Completed) RO (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000266-64 Sponsor Protocol Number: PEGF/USV/P3/003 Start Date*: 2015-06-18
    Sponsor Name:USV Limited
    Full Title: A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Pa...
    Medical condition: Duration of Sever Neutropenia and incidence of febrile neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:46:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA